Zim Laboratories — 360° view

Zim Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹105 crore and a net loss of ₹2.05 crore for the September 2026 quarter.

Zim Laboratories (NSE: ZIMLAB) closed at ₹147.80 on 20 Nov 2026. Its market capitalisation is ₹793 crore and it trades at 383.1 times earnings.

Share price
₹147.80 (20 Nov 2026)
Market cap
₹793 Cr (20 Nov 2026)
P/E
383.12 (20 Nov 2026)
Revenue
₹105 Cr (September 2026 quarter)
Net profit
₹-2 Cr (September 2026 quarter)
ROCE
4.76% (FY26)
ROE
1.59% (FY26)
Book value
₹54.5 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹159.81 / ₹110.22 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ZIMLAB

Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.